Literature DB >> 16971652

Pilot study of a commercialized human papillomavirus (HPV) genotyping assay: comparison of HPV risk group to cytology and histology.

Philip E Castle1, Mark Sadorra, Francisco Garcia, E Blair Holladay, Janet Kornegay.   

Abstract

We evaluated a commercialized PCR assay, Linear Array, that detects 37 human papillomavirus (HPV) genotypes, using a sample of liquid cytology specimens (n = 534). We found a strong association of an increasing level of HPV risk (HPV type 16 [HPV16] > HPV18 > other carcinogenic types > noncarcinogenic types > negative specimens) with increasing severities of cytologic interpretations (P(Trend) < 0.0005) and histologic diagnoses (P(Trend) < 0.0005).

Entities:  

Mesh：

Year:  2006        PMID： 16971652      PMCID： PMC1698309          DOI： 10.1128/JCM.01305-06

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  15 in total

1.  Improved amplification of genital human papillomaviruses.

Authors:  P E Gravitt; C L Peyton; T Q Alessi; C M Wheeler; F Coutlée; A Hildesheim; M H Schiffman; D R Scott; R J Apple
Journal:  J Clin Microbiol       Date:  2000-01       Impact factor: 5.948

2.  Carcinogenicity of human papillomaviruses.

Authors:  Vincent Cogliano; Robert Baan; Kurt Straif; Yann Grosse; Béatrice Secretan; Fatiha El Ghissassi
Journal:  Lancet Oncol       Date:  2005-04       Impact factor: 41.316

3.  A comparison of a prototype PCR assay and hybrid capture 2 for detection of carcinogenic human papillomavirus DNA in women with equivocal or mildly abnormal papanicolaou smears.

Authors:  Mark Schiffman; Cosette M Wheeler; Abhijit Dasgupta; Diane Solomon; Philip E Castle
Journal:  Am J Clin Pathol       Date:  2005-11       Impact factor: 2.493

4.  Restricted cross-reactivity of hybrid capture 2 with nononcogenic human papillomavirus types.

Authors:  Philip E Castle; Mark Schiffman; Robert D Burk; Sholom Wacholder; Allan Hildesheim; Rolando Herrero; M Concepcion Bratti; Mark E Sherman; Attila Lorincz
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2002-11       Impact factor: 4.254

5.  Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis.

Authors:  G M Clifford; S Gallus; R Herrero; N Muñoz; P J F Snijders; S Vaccarella; P T H Anh; C Ferreccio; N T Hieu; E Matos; M Molano; R Rajkumar; G Ronco; S de Sanjosé; H R Shin; S Sukvirach; J O Thomas; S Tunsakul; C J L M Meijer; S Franceschi
Journal:  Lancet       Date:  2005 Sep 17-23       Impact factor: 79.321

6.  Determinants of genital human papillomavirus detection in a US population.

Authors:  C L Peyton; P E Gravitt; W C Hunt; R S Hundley; M Zhao; R J Apple; C M Wheeler
Journal:  J Infect Dis       Date:  2001-05-09       Impact factor: 5.226

7.  The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice.

Authors:  Michelle J Khan; Philip E Castle; Attila T Lorincz; Sholom Wacholder; Mark Sherman; David R Scott; Brenda B Rush; Andrew G Glass; Mark Schiffman
Journal:  J Natl Cancer Inst       Date:  2005-07-20       Impact factor: 13.506

8.  Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral.

Authors:  Shalini L Kulasingam; James P Hughes; Nancy B Kiviat; Constance Mao; Noel S Weiss; Jane M Kuypers; Laura A Koutsky
Journal:  JAMA       Date:  2002-10-09       Impact factor: 56.272

9.  Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis.

Authors:  Mark E Sherman; Attila T Lorincz; David R Scott; Sholom Wacholder; Philip E Castle; Andrew G Glass; Iwona Mielzynska-Lohnas; Brenda B Rush; Mark Schiffman
Journal:  J Natl Cancer Inst       Date:  2003-01-01       Impact factor: 13.506

10.  Preferential risk of HPV16 for squamous cell carcinoma and of HPV18 for adenocarcinoma of the cervix compared to women with normal cytology in The Netherlands.

Authors:  S Bulk; J Berkhof; N W J Bulkmans; G D Zielinski; L Rozendaal; F J van Kemenade; P J F Snijders; C J L M Meijer
Journal:  Br J Cancer       Date:  2006-01-16       Impact factor: 7.640
View more
  16 in total

1.  Human papillomavirus genotyping after denaturation of specimens for Hybrid Capture 2 testing: feasibility study for the HPV persistence and progression cohort.

Authors:  Brandon J LaMere; Janet Kornegay; Barbara Fetterman; Mark Sadorra; Jen Shieh; Philip E Castle
Journal:  J Virol Methods       Date:  2007-07-27       Impact factor: 2.014

2.  Validation of an automated detection platform for use with the roche linear array human papillomavirus genotyping test.

Authors:  Matthew P Stevens; Suzanne M Garland; Sepehr N Tabrizi
Journal:  J Clin Microbiol       Date:  2008-09-10       Impact factor: 5.948

3.  Validation of a low-cost human papillomavirus genotyping assay based on PGMY PCR and reverse blotting hybridization with reusable membranes.

Authors:  C Estrade; P-A Menoud; D Nardelli-Haefliger; R Sahli
Journal:  J Clin Microbiol       Date:  2011-08-10       Impact factor: 5.948

4.  Comparison of real-time multiplex human papillomavirus (HPV) PCR assays with the linear array HPV genotyping PCR assay and influence of DNA extraction method on HPV detection.

Authors:  Christine C Roberts; Ryan Swoyer; Janine T Bryan; Frank J Taddeo
Journal:  J Clin Microbiol       Date:  2011-02-23       Impact factor: 5.948

5.  Comparison of linear array and line blot assay for detection of human papillomavirus and diagnosis of cervical precancer and cancer in the atypical squamous cell of undetermined significance and low-grade squamous intraepithelial lesion triage study.

Authors:  Philip E Castle; Patti E Gravitt; Diane Solomon; Cosette M Wheeler; Mark Schiffman
Journal:  J Clin Microbiol       Date:  2007-11-07       Impact factor: 5.948

6.  A modified Latent Class Model assessment of human papillomavirus-based screening tests for cervical lesions in women with atypical glandular cells: a Gynecologic Oncology Group study.

Authors:  Randy L Carter; Le Kang; Kathleen M Darcy; James Kauderer; Shu-Yuan Liao; William H Rodgers; Joan L Walker; Heather A Lankes; S Terence Dunn; Eric J Stanbridge
Journal:  Cancer Causes Control       Date:  2012-10-17       Impact factor: 2.506

7.  Human papillomavirus genotype specificity of hybrid capture 2.

Authors:  Philip E Castle; Diane Solomon; Cosette M Wheeler; Patti E Gravitt; Sholom Wacholder; Mark Schiffman
Journal:  J Clin Microbiol       Date:  2008-06-25       Impact factor: 5.948

8.  A comparison of linear array and hybrid capture 2 for detection of carcinogenic human papillomavirus and cervical precancer in ASCUS-LSIL triage study.

Authors:  Patti E Gravitt; Mark Schiffman; Diane Solomon; Cosette M Wheeler; Philip E Castle
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-05       Impact factor: 4.254

9.  Evaluation of a prototype real-time PCR assay for carcinogenic human papillomavirus (HPV) detection and simultaneous HPV genotype 16 (HPV16) and HPV18 genotyping.

Authors:  Philip E Castle; Mark Sadorra; Tiffany Lau; Carrie Aldrich; Francisco A R Garcia; Janet Kornegay
Journal:  J Clin Microbiol       Date:  2009-08-12       Impact factor: 5.948

10.  Carbonic anhydrase IX and human papillomavirus as diagnostic biomarkers of cervical dysplasia/neoplasia in women with a cytologic diagnosis of atypical glandular cells: a Gynecologic Oncology Group study in United States.

Authors:  Shu-Yuan Liao; William H Rodgers; James Kauderer; Thomas A Bonfiglio; Joan L Walker; Kathleen M Darcy; Randy Carter; Masayuji Hatae; Lyuba Levine; Nick M Spirtos; Eric J Stanbridge
Journal:  Int J Cancer       Date:  2009-11-15       Impact factor: 7.396
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.